The cancer stem cell (CSC) model proposes that cells within a tumor are organized in a hierarchical lineage relationship and display different tumorigenic potential, suggesting that effective therapeutics should target rare CSCs that sustain tumor malignancy. Here we review the current status of studies to identify CSCs in human prostate cancer as well as mouse models, with an emphasis on discussing different functional assays and their advantages and limitations. We also describe current controversies regarding the identification of prostate epithelial stem cells and cell types of origin for prostate cancer, and present potential resolutions of these issues. Although definitive evidence for the existence of CSCs in prostate cancer is still lacking, future directions pursuing the identification of tumor-initiating stem cells in the mouse may provide important advances in evaluating the CSC model for prostate cancer.
The cancer stem cell (CSC) model proposes that cells within a tumor are organized in a hierarchical lineage relationship and display different tumorigenic potential, suggesting that effective therapeutics should target rare CSCs that sustain tumor malignancy. Here we review the current status of studies to identify CSCs in human prostate cancer as well as mouse models, with an emphasis on discussing different functional assays and their advantages and limitations. We also describe current controversies regarding the identification of prostate epithelial stem cells and cell types of origin for prostate cancer, and present potential resolutions of these issues. Although definitive evidence for the existence of CSCs in prostate cancer is still lacking, future directions pursuing the identification of tumor-initiating stem cells in the mouse may provide important advances in evaluating the CSC model for prostate cancer. Keywords: cancer stem cell; prostate cancer; mouse models; cell of origin; tumor-initiating cell
The cancer stem cell (CSC) model has attracted considerable interest in recent years due to its implications in cancer prognosis and clinical management. In its strictest form, the CSC model posits a hierarchical organization of tumors, with cancer stem cells at the top of the lineage hierarchy being capable of indefinite self-renewal, unlike their progeny, which undergoes an epigenetic program of differentiation and loss of tumorigenicity (Reya et al., 2001; Marotta and Polyak, 2009; Rosen and Jordan, 2009; Shackleton et al., 2009) . In this view, rare CSCs may represent the driving force of tumor malignancy, and therefore effective treatment could be achieved by specific targeting of the CSC population.
In contrast, the stochastic (clonal) evolution model proposes that most of the cancer cells within a tumor are highly tumorigenic and possess different genetic or epigenetic properties (Marotta and Polyak, 2009; Rosen and Jordan, 2009; Shackleton et al., 2009) . Clones can arise in the tumor population that have distinct growth advantages and/or therapy resistance, and thereby drive the malignant evolution of the tumor. Thus, in the clonal evolution model, it is essential to eliminate nearly all cancer cells to achieve therapeutic efficacy. In theory, these two models do not need to be mutually exclusive. Cancers that follow the CSC model may as well undergo clonal evolution if more than one type of CSCs coexist or CSCs are under environmental selection (Barabe et al., 2007; Marotta and Polyak, 2009 ).
As it is not experimentally feasible to investigate the potential existence of CSCs in human tumors solely on the basis of these theoretical definitions, CSCs are instead defined in practical terms through the use of several functional assays. The most frequently used methodology involves xenotransplantation of flowsorted populations of primary cancer cells into immunodeficient mice. In this assay, CSCs are defined as a subpopulation of cells within a primary tumor that can initiate tumor formation in mice following transplantation, unlike the remaining tumor cells. Using this assay, early studies identified CSC populations in hematological malignancies, such as the CD34 þ CD38 À population in acute myeloid leukemia (Lapidot et al., 1994; Bonnet and Dick, 1997; Wang and Dick, 2005; Barabe et al., 2007) . Similar approaches were subsequently applied to solid tumors, leading to the identification of candidate CSC populations that were prospectively enriched using specific markers in breast (CD44 þ CD24 À Lin À ), brain (CD133 þ ) and colon cancers (CD133 þ ) (Al-Hajj et al., 2003; Singh et al., 2004; O'Brien et al., 2007; RicciVitiani et al., 2007) . Overall, however, the available evidence supporting the identification of CSCs in solid tumors has been less convincing, at least in part because solid tumor cells exist in a complex microenvironment that is not readily modeled by xenotransplantation (Hill, 2006) .
Much of the confusion in the literature arises through inconsistencies in nomenclature within the field. In particular, due to the wide use of xenotransplantation as a functional assay for CSCs, transformed cells that can initiate tumor formation in this assay are often referred to as CSCs in the literature. However, a tumorinitiating cell (TIC) represents a different concept from that of a CSC, as TICs unquestionably exist within tumors and their identification does not by itself imply a hierarchical organization of a tumor. Indeed, the majority of cells within a tumor could potentially possess TIC properties and nonetheless follow a clonal evolution model. Consequently, it is important to distinguish CSCs that have been strictly defined by their position and function within a lineage hierarchy in vivo from CSCs that have been identified as rare TICs in transplantation studies.
A similar confusion arises with respect to the cell of origin for cancer, which corresponds to a normal tissue cell that is the target for the initiating events of tumorigenesis. In principle, a normal adult stem cell could be a logical cell of origin for cancer, as it would retain the ability to self-renew and generate a hierarchy of differentiated lineages within a tumor. However, it is also possible that a cell of origin could correspond to a downstream progenitor cell or conceivably even a terminally differentiated cell that acquires stem cell properties during oncogenic transformation. For example, both hematopoietic stem cells as well as committed progenitor cells can initiate leukemia after transformation (Cozzio et al., 2003; Huntly et al., 2004; Passegue et al., 2004) . More recently, activation of canonical Wnt signaling has been shown to transform mouse intestinal stem cells to give rise to adenocarcinomas (Barker et al., 2009; Zhu et al., 2009) . Notably, although normal tissue stem cells could represent a cell of origin for cancer and may acquire the properties of TICs after transformation, such transformed cells might not correspond to CSCs and their existence might be compatible with either a CSC or clonal evolution model. Below, we discuss the current status of the CSC model as applied to prostate cancer. We also review current controversies with regards to the identification of normal prostate epithelial stem cells and cell types of origin, in both human prostate tumors as well as in mouse models.
Studies of prospective human prostate cancer stem cells
In human and mouse, the normal prostate gland epithelium contains three primary differentiated cell types (Abate- Shen and Shen, 2000; Shen and AbateShen, 2010) . Luminal cells are columnar epithelial cells that express secretory proteins as well as markers such as cytokeratin 8 (CK8), CK18, Nkx3.1, prostate-specific antigen and high levels of androgen receptor (AR). Basal cells are localized beneath the luminal layer and express markers including CK5, CK14 and p63, but express low levels of AR. A rare third type of cells termed neuroendocrine cells express endocrine markers such as synaptophysin and chromogranin A, but do not express AR.
Prostatic intraepithelial neoplasia (PIN) is often considered a precursor of prostate cancer, and is characterized histologically by luminal epithelial hyperplasia and a progressive loss of basal cells (Abate- Shen and Shen, 2000; Shen and Abate-Shen, 2010) . As the disease progresses to adenocarcinoma, the loss of basal cells becomes complete resulting in the strong luminal phenotype of prostate cancer. Initially, human prostate cancers rely on androgens for survival and thus treatment of prostate cancer often utilizes androgen-deprivation therapy. However, the disease will almost certainly recur in a castration-resistant form (formerly referred to as androgen-independent), which is essentially incurable Attard et al., 2009) . This has led to the notion that CSCs in advanced prostate cancer should be castration resistant.
Similar to other solid tumors, it is presently unclear whether prostate cancers are organized hierarchically and follow the CSC model. In principle, a CSC model of prostate cancer progression can be conceived, which also incorporates features of clonal evolution (Figure 1 ). In this model, cancer-initiating mutations could occur in different cells of origin within the prostate epithelium. During prostate cancer progression, clonal progeny of the resulting TICs are constantly under selection, including responses to treatment. Some of these clones may gain additional growth and survival advantages and become the driving force of tumor malignancy, acquiring the properties of CSCs. Below, we consider the published experimental data that are crucial for the evaluation of this and other theoretical models.
Identification of putative human prostate CSCs
A variety of studies have reported the identification of CSCs in prostate cancer, using a range of functional assays. Studies that have investigated human prostate CSCs have either used primary tumor cells for cell culture assays of stem cell properties, or instead have used established cell lines or xenografts in cell culture and grafting assays in immunodeficient mice (Figure 2) . One notable study from the Maitland and Collins laboratories has used flow cytometry to isolate CD44 þ /a2b1 hi /CD133 þ cells from primary human tumors, and showed that this population displayed high proliferative potential in colony-forming assays, as well as the ability to differentiate to a luminal phenotype in culture (Collins et al., 2005) . A subsequent study performed gene expression profiling to identify markers specific for the related a2b1 hi /CD133 þ population (Birnie et al., 2008 Other studies have reported the isolation of putative prostate CSCs from established human prostate cancer cell lines, using similar combinations of cell-surface markers. For example, CD44
þ /a2b1 hi /CD133 þ cells were isolated from the DU145 cell line (Wei et al., 2007) , whereas CD133 hi cells were identified from human telomerase reverse transcriptase-immortalized primary tumor-derived prostate epithelial cell lines (Miki et al., 2007) , and CD44 þ CD24 -cells were isolated from the LNCaP cell line (Hurt et al., 2008) . In addition, the Pten/PI3K/Akt pathway has been shown to be critical for the tumorigenicity of CD44 þ CD133 þ cells in the PC3 and DU145 cell lines (Dubrovska et al., 2009) . The CSC properties of these cell populations were primarily demonstrated by colony formation assays and tumor initiation following subcutaneous injection. Other studies have demonstrated tumor formation from sub-populations of human prostate cell lines using renal grafting assays . Perhaps most interestingly, holoclones from the PC3 prostate cancer cell line were shown to contain cells expressing high levels of CD44, a2b1 and b-catenin, and could initiate serially transplantable tumors after subcutaneous injection (Li et al., 2008) .
Finally, these approaches have been used to identify putative CSCs from prostate tumor xenografts that have been established from primary tumors, either by passaging through cell culture or through serial passaging in immunodeficient mice. Most notably, the Tang laboratory has identified CD44 þ /a2b1 hi cells from human LAPC9 xenografts as candidate prostate CSCs, based on colony formation assays and tumor initiation following subcutaneous or orthotopic injection (Patrawala et al., 2005 (Patrawala et al., , 2006 (Patrawala et al., , 2007 .
Limitations of current approaches
Despite these promising studies, there are several key experimental limitations to current methods for identification of prostate CSCs. First, to date, tumorinitiation has not yet been demonstrated for flow-sorted sub-populations isolated from primary prostate tumors. This fundamental limitation may be due to the relative indolence of many prostate cancers, and/or due to the difficulty in culturing prostate cells with luminal phenotypes, even for a limited time. As a consequence, most work has utilized established prostate cancer cell lines or xenografts. However, after establishment in culture followed by extensive passaging, the genetic properties of cell lines are likely to be different from human primary tumors, as it is extremely difficult to culture primary prostate cancer cells (Peehl, 2005) . Established xenografts may be more similar to primary tumors, but recent studies of melanomas have suggested that xenografts display significantly higher frequencies of TICs relative to primary tumors (Boiko et al., 2010) .
Secondly, assays utilized for demonstration of prostate CSC properties can be flawed. In particular, twodimensional colony formation assays in culture may selectively favor cells that better adapted to the culture conditions, and may not accurately model microenvironmental conditions in vivo. Similar concerns apply to in vivo assays, as several studies employ subcutaneous injection to assess tumor-initiation, and thus are not conducted within a prostate microenvironment. Orthotopic injection of human cells into immunodeficient mice alleviate this concern, but also face the issue of crossspecies compatibility, possibly resulting in variable outcomes and underestimation of tumorigenicity. Notably, technical improvements in xenotransplantation methodology can significantly increase the efficiency of tumor-initiation assays, with up to 25% of melanoma cells displaying TIC properties (Quintana et al., 2008) . Thus, the use of more highly immunodeficient mice, orthotopic xenotransplantation and tissue reconstitution with prostate stromal cells may all improve the efficiency and specificity of tumor-initiation assays. However, it remains unclear whether these technical improvements will substantially affect tumor-initiation frequency in many cancers (Ishizawa et al., 2010) .
Third, the specificity of the cell-surface markers utilized in these studies is unclear and their biological function is often unknown. Although CD44 and CD133 have been implicated as CSC markers in a variety of tissues (Uchida et al., 2000; Al-Hajj et al., 2003; Richardson et al., 2004; Singh et al., 2004) , their specificity for identification of CSC populations has been questioned. For example, the expression pattern of CD44 in both benign and malignant human prostate lesions varies in different reports, and its relationship with tumor grade is controversial (Patrawala et al., 2006; Ugolkov et al., 2010) . Furthermore, CD133 is broadly expressed in luminal cells of colon, lung and pancreas, and appears to display little specificity for colon cancer-initiating cells (Shmelkov et al., 2008) . Moreover, the apparent expression pattern of CD133 may vary greatly according to the staining conditions used, as the most commonly used antibody recognizes a glycosylated epitope (Shmelkov et al., 2008) . One recent study found that CD133 þ cells from the DU145 cell line were not more clonogenic than CD133 À cells, while CD133 was not expressed in other prostate cell lines examined (Pfeiffer and Schalken, 2010) . Finally, another study has shown that mouse CD133 is widely expressed Figure 2 Strategies for identification of human prostate CSCs using different functional assays. In some studies, dissociated cells from primary tumors have been flow sorted using cell-surface markers and CSC (black) properties analyzed by colony formation assays in culture (red arrows). In other studies, CSCs were isolated from cultured prostate cancer cell lines or xenografted tumors and analyzed by colony formation assays and tumor growth following subcutaneous injection into mice (green arrows). However, tumor initiation from specific cell populations isolated from primary human prostate tumors has not been demonstrated to date (red dashed arrow).
by prostate luminal cells, whereas human CD133 is less broadly expressed in benign tissue, but is upregulated in regions of inflammation within tumors, suggesting a lack of association with CSCs (Missol-Kolka et al., 2010) . Thus, the utility of putative CSC markers for identification of prostate CSCs or for clinical prognosis remains unclear.
Over time, the CSC nomenclature has become increasingly non-specific in the published literature. As it remains difficult to evaluate the hierarchical organization of solid tumors, the strict in vivo definition of CSCs has not yet been experimentally demonstrated in prostate cancer. Instead, current efforts in the field have been focused on the identification of rare TICs using transplantation assays in a heterologous microenvironment. Even by this standard, however, prostate CSCs have not been satisfactorily demonstrated, as they have not been isolated from primary human tumors and unequivocally shown to have higher tumor-initiating capability than non-CSC populations in xenotransplantation assays. Consequently, at present there is relatively little evidence that human prostate cancer adheres to a CSC model.
Studies of prospective mouse prostate cancer stem cells
Given the technical issues associated with direct identification of human prostate CSCs/TICs, mouse models represent an important alternative to investigate the CSC model in prostate cancer. Mouse models are advantageous as they can largely circumvent the crossspecies transplantation issue and as candidate CSCs can be analyzed from genetically defined tumors in vivo. For example, several studies have utilized flow cytometry approaches to identify candidate CSCs in mouse models of breast cancer, including the MMTV-Wnt-1, MMTVerbB2 and p53 null models (Cho et al., 2008; Vaillant et al., 2008; Zhang et al., 2008) . However, to what extent the CSCs in these mouse models recapitulate human cancers is not clear. For example, distinct genetic models of breast cancer have yielded different outcomes with respect to conforming to the CSC model (Vaillant et al., 2008) .
To date, mouse prostate cancer models have not been extensively evaluated with respect to tumor-initiation assays and the identification of candidate CSCs. Notably, one study has shown that flow-sorted Lin À Sca-1 þ CD49f high cells from a Pten null mouse model could display TIC properties using both sphere-forming assays in culture and following renal grafting in vivo, which gave rise to carcinoma lesions in the resulting grafts (Mulholland et al., 2009) . A similar approach has been recently used to isolate Lin À Sca-1 þ cells from tumors in a conditional Pten deletion model, and showed that cancer-associated fibroblasts can significantly potentiate the stemness and growth-properties of these candidate CSCs in renal grafts (Liao et al., 2010) .
Although these studies avoid the technical issues associated with cross-species transplantation, the extent to which renal grafting assays can recapitulate the endogenous prostate cancer microenvironment remains an issue for their interpretation. Moreover, the markers used for flow sorting of putative CSCs require further validation, both in mouse and in human prostate. For example, one recent study found that the proportion of Sca-1 þ cells first increases and then decreases in tumors of TRAMP (transgenic adenocarcinoma mouse prostate) mice after castration, perhaps in agreement with a role for Sca-1 þ CSCs in castration-resistant cancer progression (Tang et al., 2009) . Nevertheless, it is already apparent that mouse models will be of tremendous utility for mechanistic investigations of putative CSCs in prostate cancer.
Identification of normal prostate epithelial stem cells in mice
As a CSC may originate from oncogenic transformation of a normal tissue stem cell, many studies have focused on the identification of normal prostate epithelial stem cells as a starting point for subsequent studies to determine whether genetic alterations of these stem cells may confer tumor-initiating properties. However, studies from different laboratories have used distinct experimental methodologies, and have identified potentially non-overlapping candidate stem cell populations. The identification of these candidate stem cells has led to examination of whether these populations in the mouse or analogous populations in human can serve as cells of origin for prostate cancer, and has engendered similar controversies.
Adult prostate epithelial stem cells are unlikely to divide continuously to maintain tissue homeostasis, unlike stem cell populations in the epidermis and intestine. Consequently, the growth-quiescence of the normal adult prostate epithelium might imply that prostate stem cells do not exist. However, it is very likely that adult prostate epithelial stem cells function in the context of androgen-mediated prostate regeneration. Although the prostate regresses following androgendeprivation treatment, it will regenerate back to its hormonally-intact size when physiological levels of androgen are restored, and this process of serial regression and regeneration can be repeated for many cycles (Isaacs, 1985; Tsujimura et al., 2002) . This phenomenon indicates that adult prostate epithelial stem cells exist in the regressed state, perhaps behaving similarly to quiescent stem cells in other tissues that respond to wound repair and function in tissue regeneration.
Following androgen ablation, 90% of the luminal cells, but only a small percentage of basal cells will undergo apoptosis during the process of regression (English et al., 1987; Evans and Chandler, 1987) . Consequently, early studies favored a basal localization of stem cells, as most basal cells are castration resistant. Moreover, immunostaining analyses of gene expression identified 'intermediate' cells in the basal layer, which coexpress both basal-specific and luminal-specific CKs, as well as the luminal marker prostate-specific antigen (Verhagen et al., 1988; Bonkhoff et al., 1994; van Leenders et al., 2000) . These observations suggested a model in which basal stem cells give rise to intermediate 'transit-amplifying' cells that are progenitors for luminal cells (Bonkhoff and Remberger, 1996) , although this lineage relationship lacked experimental verification.
Some evidence has also supported the existence of luminal epithelial stem cells. Most notably, although p63 is a marker of basal cells, and p63 null mutant mice fail to form prostate (Mills et al., 1999; Yang et al., 1999; Signoretti et al., 2000) , grafting of urogenital rudiments from p63 null cells could rescue tissue with prostatic ductal structures (Kurita et al., 2004) . Although these prostate grafts lacked basal cells, they nonetheless could undergo multiple rounds of regression/regeneration (Kurita et al., 2004) .
As discussed below, more recent studies have adopted two distinct experimental approaches for the identification of prostate epithelial stem cells. Notably, flow cytometry and tissue reconstitution approaches have identified basal stem cells, whereas a genetic lineagemarking approach has identified luminal stem cells.
Flow cytometry-based approaches
One major approach to identify normal prostate epithelial stem cells has been to use cell-surface markers for isolation of cell populations by flow cytometry, followed by assaying their stem cell properties by tissue reconstitution in renal grafts. This tissue reconstitution assay is based on the pioneering work of (Cunha and Lung, 1978) who showed that combination of normally quiescent adult prostate tissue with embryonic urogenital mesenchyme (UGM) in renal grafts could stimulate formation of new prostatic ducts. This assay has been further developed by the Witte group, who used dissociated prostate epithelial cells together with rat UGM for tissue reconstitution in renal grafts (Xin et al., 2003) .
Using this assay, the Wilson and Witte laboratories showed that Sca-1 þ cells were more efficient in generating prostatic tissues than Sca-1 À cells, and thus were enriched for candidate prostate stem cells (Burger et al., 2005; Xin et al., 2005) . Further studies using prostate colony-and sphere-forming assays in culture as well as tissue reconstitution assays have shown that prostate stem cell populations could be further enriched in combination with markers such as CD49f and Trop2 (Lawson et al., 2007; Goldstein et al., 2008) . Importantly, these Lin
þ populations express basal markers such as CK5 and CK14, but express low levels of luminal markers such as CK8, CK18 and AR (Lawson et al., 2007) . Other studies have employed cell-surface markers such as CD44 and CD133 for enrichment of prostate stem cell populations. Notably, 10% of single Lin
þ cells were reported to be capable of prostate reconstitution in the renal grafting assay (Leong et al., 2008) . However, it is less clear whether the responsible cells are basal or luminal in this study, as Lin
þ cells are both basal and luminal in the mouse prostate epithelium, but exclusively basal in the human prostate epithelium (Leong et al., 2008) ; a further complication arises from a previous report that CD117 (c-kit) is not expressed within the prostate epithelium (Simak et al., 2000) . Overall, these different studies in the literature have used distinct marker combinations and thus raise the possibility that they are not defining similar cell populations.
Although it represents a powerful methodology, the renal graft tissue reconstitution assay may have limitations for identification of adult prostate stem cells. As noted above, adult prostate epithelial stem cells are likely to correspond to quiescent cells that can drive the process of regeneration during androgen restoration to the regressed state. However, it is unclear whether the renal graft tissue reconstitution assay accurately models the process of prostate epithelial regeneration. In particular, this approach relies upon the use of a heterologous stromal component (embryonic UGM) that promotes epithelial proliferation and differentiation, and may alter the properties of adult prostate epithelial progenitors (Risbridger and Taylor, 2008) . Thus, the epithelial cells used for tissue reconstitution in renal grafts are removed from their original microenvironment, perhaps comprising a stem cell niche, and are instead placed in the context of embryonic mesenchyme, which may reprogram their fates. Thus, the ability of isolated cells to reconstitute prostate ducts in this assay may not represent definitive evidence that they correspond to stem cells in vivo, as conceivably non-stem cells could be reprogrammed to yield similar outcomes in this assay. Furthermore, the removal of epithelial cells from their normal microenvironment may lead to a failure to survive and/or proliferate, whereas UGM might not always represent a permissive environment to display stem cell properties.
In addition to the use of mice, several studies have utilized flow cytometry-based approaches to isolate candidate prostate epithelial stem cells directly from primary human tissue, and have shown that these stem cells are basal. In particular, human prostate epithelial cells expressing high levels of a 2 b 1 -integrin performed better than the total basal population in colony formation assays, as well as in prostate duct reconstitution after subcutaneous injection (Collins et al., 2001) . A subsequent study showed that further enrichment of prospective human stem cells can be carried out using the marker CD133 (Richardson et al., 2004) . Similarly, the Trop2 marker can be used in combination with CD49f to enrich sphere-forming cells from the human prostate (Goldstein et al., 2008) . Furthermore, the Witte group has shown that human prostate sphere-forming cells are predominantly basal, and can reconstitute prostatic tissue after recombination with UGM and subcutaneous injection into immunodeficient SCID mice . As is the case with the analogous studies carried out in the mouse, it remains unclear whether these isolated cell populations truly behave as adult stem cells in the human prostate.
Genetic lineage marking
An alternative method for identification of adult stem cells involves genetic lineage marking of progenitor cells, followed by analysis of progeny differentiation in vivo, as has initially been demonstrated for stem cells in the Drosophila ovary, testis and intestine (Spradling et al., 2008) . Analogous studies in the mouse have used genetic lineage marking to identify stem cell populations in the intestine, stomach and hair follicle (Barker et al., 2007 Snippert et al., 2010) . In the mouse, this methodology generally utilizes a cell type-specific inducible Cre recombinase to drive genetic recombination events in cell types of interest. Typically, Cre recombinase can be made inducible through fusion with truncated-steroid hormone receptors, such as the estrogen receptor (ER), which have been engineered to be unresponsive to endogenous estradiol and instead can be activated by tamoxifen (Feil et al., 1997; Indra et al., 1999) . In combination with an appropriate Cre reporter allele, induction of recombination results in cell marking through the expression of a reporter such as yellow fluorescent protein (YFP), so that these specific cells and their progeny can be indelibly marked and followed in vivo. This method also allows the simultaneous deletion or activation of genes of interest (such as oncogenes), so that the targeted cells can both be marked and mutated. Thus, this methodology is highly suitable for the investigation of normal adult stem cells, as well as TICs, as organ development and tumor formation occur within an intact in vivo environment, rather than in heterologous graft sites.
However, there are also several potential caveats for the genetic lineage-marking approach. One important issue is the specificity of the lineage-marking methodology, which requires careful control to ensure that activation of the inducible Cre recombinase takes place only in the cells of interest, and not in ectopic cell types, as is sometimes observed. Another limitation is that transient administration of tamoxifen may perturb normal cell behavior, which is a particular concern in hormonally responsive tissues such as the prostate. Finally, the inducible Cre allele itself may alter cellular properties, as gene targeting to place Cre recombinase under the control of a specific promoter may also alter the function of the endogenous locus. Ideally, these limitations in the identification of stem cells by lineage marking should be circumvented by validation using additional experimental approaches.
Our laboratory has recently applied this lineagemarking methodology to identify a rare luminal epithelial population with stem cell properties during prostate regeneration . These cells, which we term CARNs (Castration-resistant Nkx3.1-expressing cells) can be marked using a genetically engineered mouse line in which the activity of an inducible Cre ERT2 recombinase is under the control of the endogenous promoter for Nkx3.1. Interestingly, Nkx3.1 encodes a homeodomain transcription factor that represents the earliest specific marker for the prostate epithelium in organogenesis, and is also frequently downregulated during prostate cancer initiation (Abate- Shen et al., 2008) . Although all luminal cells as well as a small percentage of basal cells in the hormonally intact adult prostate express Nkx3.1, only rare luminal CARNs express Nkx3.1 in the regressed epithelium .
Thus, after Cre activation by tamoxifen treatment in Nkx3.1
CreERT2/ þ , R26R-YFP/ þ castrated males, we observed yellow fluorescent protein expression in rare luminal epithelial cells, corresponding to lineage-marked CARNs. Following androgen-mediated prostate regeneration, we observed that lineage-marked YFP þ progeny was present in both luminal (CK18 þ ) and basal (CK5 þ , p63 þ ) compartments, indicating that the CARNs population contains a bipotential progenitor. Furthermore, evidence for short-term and long-term self-renewal was obtained from BrdU-labeling experiments during prostate regeneration, as well as from the persistence of lineaged-marked cells after multiple rounds of serial regression/regeneration. In further studies, we showed that single-cell transplantation of lineage-marked CARNs resulted in formation of prostatic ducts in renal grafts that contained all three prostate epithelial cell types, indicating multipotency of CARNs. Taken together, these data provide strong evidence for the stem cell properties of CARNs in prostate regeneration, using both in vivo lineage marking as well as tissue reconstitution assays.
These findings suggest two possible models for the function of CARNs in the prostate epithelium . One model is that basal and luminal stem cell populations may coexist within the prostate epithelium, and that CARNs serve as luminal stem cells. Alternatively, CARNs might correspond to facultative stem cells, corresponding to luminal progenitors that acquire stem cell properties following androgen deprivation. In this second model, CARNs would be functionally indistinguishable from other adult prostate stem cells, and would represent the stem cells that drive prostate epithelial regeneration, which can be considered analogous to a wound-healing response. These two models have different implications for interpreting the role of CARNs as cells of origin for prostate cancer, as discussed below.
In summary, flow cytometry-based approaches have identified distinct prostate basal cell populations, whereas a genetic lineage-marking approach has identified a luminal stem cell population (CARNs). Notably, these putative stem cell populations have been assayed for their functional properties using different experimental assays. As CARNs have been shown to display stem cell properties in vivo, they may be particularly relevant for understanding the origin of prostate cancer.
Cell of origin and TICs
The identification of normal cells that can serve as a cell of origin for prostate cancer is highly relevant for understanding the applicability of a CSC model, and is currently under intense investigation. The cell of origin may also have clinical significance, as in the case of breast cancer, distinct tumor subtypes have been proposed to originate through transformation of different progenitors within the mammary epithelial lineage hierarchy (Lim et al., 2009; Visvader, 2009; Molyneux et al., 2010) . Thus, it is conceivable that there may be distinct cells of origin for other epithelial cancers, and different cells of origin may give rise to clinically relevant subtypes that differ in their prognosis and treatment outcome.
Basal cells as a cell of origin Although prostate tumors display a strongly luminal phenotype, this does not exclude the possibility that basal cells could be a cell of origin for prostate cancer. In particular, it is possible that transformed basal cells could differentiate to generate large numbers of luminal cancer cells. For example, prostate-specific conditional deletion of Pten by a probasin-Cre driver allele has been shown to result in a basal cell expansion accompanied by increased number of intermediate cells, suggesting a basal cell of origin (Wang et al., 2006) . Other studies investigating the capabilities of basal cells have primarily utilized flow -cytometry-based approaches (Figure 3a) . In particular, mouse Lin
high cells correspond to a predominantly basal population, yet can differentiate into luminal cells in grafts (Lawson et al., 2007) . Furthermore, grafting of Lin -Sca-1 þ CD49f high cells together with FGF10-expressing UGM produced multifocal glandular carcinoma similar to the small glandular structures observed in human prostate cancer (Lawson et al., 2010) . Similarly, lentiviral overexpression of ERG1 in Lin
high cells resulted in a PIN phenotype, while co-activation of Akt and AR signaling resulted in adenocarcinoma. However, these mouse tumors do not always recapitulate the luminal features of human prostate cancer, as expression of the basal marker p63 is frequently observed in these tumors (Lawson et al., 2010) .
An important recent study from the Witte laboratory has used similar approaches with primary human prostate tissues to show that basal cells are a cell of origin for human prostate cancer 
Trop2
hi cells resulted in high-grade PIN, and coexpression of these two genes together with AR resulted in adenocarcinoma with strong resemblance to clinical prostate cancer.
In contrast with basal cells, no prostate ducts formed using either infected or uninfected luminal cells in this study . However, the failure of luminal cells to form prostate ducts when combined with UGM and matrigel may indicate that luminal cell outgrowth is disfavored in this heterologous environment. As luminal cells do not grow under these conditions, it remains possible that basal stem cells can give rise to luminal cells that are the actual target of tumor initiation in reconstituted tissue within these grafts. Moreover, it is conceivable that the overexpression of AR may actually drive basal cells toward a luminal fate and thereby facilitate their transformation. Nonetheless, the work of Goldstein and colleagues provides the first strong evidence that oncogenic transformation of basal cells can result in tumors with the luminal features of human prostate cancer.
Luminal cells as a cell of origin
Other studies have provided evidence that luminal cells can serve as cells of origin for prostate cancer. For example, pathological analysis of high-grade PIN samples, which still retain basal cells, suggest that molecular events associated with human prostate cancer initiation such as upregulation of c-MYC and shortening of telomere length occur exclusively in luminal cells but not their basal neighbors (Meeker et al., 2002; Gurel et al., 2008) . In mouse models, a recent study using a prostate-specific antigen-Cre, Pten loxP/loxP prostate cancer model reported that the initial hyperplastic cells were all luminal (Korsten et al., 2009) . Finally, our laboratory has shown that targeted deletion of Pten in CARNs resulted in high-grade PIN and carcinoma, indicating that CARNs are a cell of origin . At present, however, it is unknown whether CARNs exist in the hormonally intact prostate epithelium, and if so, whether these cells can serve as cells of origin. Indeed, if CARNs correspond to facultative stem cells, as discussed above, they may correspond to a cell state that is only acquired in the regressed epithelium. Therefore, as CARNs can currently only be visualized in Figure 3 Analysis of prostate TICs in mouse models. (a) Identification of mouse prostate TICs using a renal grafting tissue reconstitution assay. Dissociated mouse prostate cells are flow sorted using cell-surface markers, followed by lentiviral infection for expression of oncogenes to induce transformation. (b) Lineage analysis for identification of prostate TICs. Genetic lineage marking is used to induce transformation of specific cell types followed by tumor growth in the prostate in vivo. Tumor cells can be dissociated and analyzed by renal grafting to compare phenotypes of tumors generated using these two different approaches.
the regressed prostate, the identification of other molecular markers for CARNs will be invaluable in addressing this central question.
In principle, the approach of genetic lineage marking can be extended to other cell types and prostate cancer models. The advantage of this methodology is that the tumor-initiating capability of cells can be readily tested by introducing genetically defined mutations in vivo, allowing growth and assessment of tumors in their natural environment (Figure 3b) . To test the CSC model, tumors derived from these genetic models can be analyzed for any features of hierarchical heterogeneity and compared with human disease samples. In addition, lineage-marked TICs may also be transplanted in renal graft assays to compare tumors derived using these two different methods (Figure 3b ). Given the complexity of human prostate cancers, it is likely that distinct mouse models may only recapitulate properties of specific subtypes of human prostate cancer, not all of which may follow a CSC model.
As in the case of the normal prostate epithelial stem cell, it is important to note that these studies on the cell of origin for prostate cancer are not mutually inconsistent, in part because they employ distinct functional assays. On balance, we favor genetic lineage marking and inducible tumorigenesis in vivo as evidence for a cell of origin as tumor formation occurs in the endogenous site without disruption of putative niche interactions, whereas transplantation assays may not recapitulate an authentic prostate tissue microenvironment. However, there may also be multiple cells of origin for prostate cancer. By analogy with breast cancer (Visvader, 2009) , it may be the case that distinct cells of origin give rise to prostate cancer that display different subtypes. Such subtypes might correspond to rare pathological variants that in total account for less than 5-10% of disease cases (Mazzucchelli et al., 2008) , or to molecular subtypes that are now being defined through comprehensive oncogenomic analyses (Taylor et al., 2010) . Importantly, as such subtypes might differ in their prognosis and/or response to treatment, the investigation of cells of origin for prostate cancer might have important clinical implications.
Role of AR
The functional role of AR in prostate TICs and CSCs has received relatively little attention in the literature. Expression of AR is observed throughout human prostate cancer progression and remains at high-levels in castration-resistant tumors (Attard et al., 2009; Taylor et al., 2010) . Indeed, despite the wealth of molecular mechanisms that have been documented to result in castration resistance, all of these mechanisms result in upregulation of AR signaling activity Attard et al., 2009) .
In this context, it is perhaps unexpected that the existing literature has suggested that prostate CSCs are AR-negative. For example, CD133 þ cells in clinical prostate specimens and CD44 þ cells from human prostate cancer cell lines have been reported to be AR - (Patrawala et al., 2006; Miki et al., 2007) . These findings appear to be inconsistent with the documented function of AR in prostate cancer progression and mechanisms of castration resistance, as has been noted previously (Sharifi et al., 2006) . Instead, the upregulation of AR activity through cancer progression is consistent with selection for a castration-resistant AR þ CSC that can generate tumor cells that are themselves castration resistant. In contrast, it is unclear how castration resistance involving upregulation of AR activity could be selected for in non-AR-expressing CSCs. Moreover, the ability of putative AR À CSCs to differentiate into AR þ cancer cells in sphere formation or renal graft assays does not readily resolve this issue, as such AR þ progeny presumably lack CSC properties, and thus should not be capable of propagating the tumor. One possibility is that these AR þ progeny could dedifferentiate into AR À CSCs, but this would suggest that such AR þ cells should be identifiable in appropriate assays as having CSC properties.
Overall, these considerations suggest that prostate CSCs, if they exist, should be AR þ , at least in more advanced stages of cancer progression. However, an earlier role for AR is also suggested by recent studies of the mechanisms for formation of TMPRSS2-ERG fusions, a chromosomal rearrangement that is found in nearly 50% of prostate adenocarcinomas, and may represent an initiating event in prostate carcinogenesis (Clark et al., 2008; Mosquera et al., 2008 Mosquera et al., , 2009 ). Studies in AR-expressing prostate cancer cell lines have shown that this chromosomal rearrangement can arise due to induced-chromosomal proximity due to AR binding to the TMPRSS2 and ERG genomic loci, followed by DNA damage and/or binding of topoisomerase II (Lin et al., 2009; Mani et al., 2009; Haffner et al., 2010) . These findings strongly suggest that TMPRSS2-ERG fusion occurs in cells expressing high levels of AR, namely luminal cells. Given the early occurrence of this rearrangement in prostate carcinogenesis, these results are also consistent with a luminal cell of origin.
Conclusions and perspectives
The frequent ineffectiveness of conventional cancer therapeutics may be explained by the CSC model, which suggests that rare therapy-resistant CSCs can repopulate and sustain tumor growth after treatment. However, similar to several other solid tumors, it is still open to debate as to whether CSCs exist in some or all prostate cancers. Even though xenotransplantation of primary human cancer cells into immunodeficient mice may significantly underestimate their tumorigenic potential, prostate CSCs have not been identified to date from human primary tumors using this assay. Furthermore, much work on isolation of prostate CSCs has neglected the importance of the prostate in vivo structures and stromal microenvironment, which might provide a niche for normal stem cells or for CSCs.
In particular, the analysis of mouse models using lineage marking and/or flow cytometry approaches has great promise for the identification of normal adult prostate stem cells and for testing their tumor-initiating capability under transformed conditions. Although the identification of mouse TICs may not necessarily support a CSC model, such approaches would allow investigation of the potential hierarchical organization of mouse prostate tumors, followed by validation in human cancers. Such studies should be instrumental in understanding prostate cancer etiology, with the ultimate hope of identifying rational drug targets.
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